With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1187173-43-8,2,7-Diazaspiro[4.5]decan-1-one hydrochloride,as a common compound, the synthetic route is as follows.,1187173-43-8
2,7-Diazaspiro[4.5]decan-1 -one hydrogen chloride (80 mg, 0.420 mmol) was dissolved in dichloromethane (4 mL) and triethylamine (0.1 17 ml_, 0.839 mmol) before the addition of 3,5-bis(trifluoromethyl)benzenesulfonyl chloride (144 mg, 0.462 mmol). After stirring for 20 h the reaction mixture was concentrated in vacuo and the resulting residue was purified by MDAP to give 7-{[3,5-bis(trifluoromethyl)phenyl]- sulfonyl}-2,7-diazaspiro[4.5]decan-1 -one (14 mg, 0.032 mmol, 8% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) delta ppm 1 .32 – 1 .63 (m, 3 H) 1.66 – 1 .76 (m, 1 H) 1 .87 – 1 .97 (m, 1 H) 2.00 – 2.08 (m, 1 H) 2.35 – 2.47 (m, 2 H) 3.15 – 3.24 (m, 2 H) 3.47 (d, J=1 1 .45 Hz, 1 H) 3.71 (d, J=1 1 .67 Hz, 1 H) 7.75 (s, 1 H) 8.32 (s, 2 H) 8.55 (s, 1 H). MS ES+ve m/z 431 (M+H).
As the paragraph descriping shows that 1187173-43-8 is playing an increasingly important role.
Reference：
Patent; CONVERGENCE PHARMACEUTICALS LIMITED; GLEAVE, Robert James; HACHISU, Shuji; PAGE, Lee William; BESWICK, Paul John; WO2011/141728; (2011); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem